BioVie reports positive Phase 2 Parkinson's data for bezisterim

Impact · against what's priced in

BioVie (BIVI) receives a positive catalyst from Phase 2 data showing bezisterim's efficacy in a high-inflammation Parkinson's subgroup and a 70% reduction in worsening risk. IXICO (IXI) sees negligible impact as the mention of its general performance and biomarker strategy lacks specific new catalysts.

BIVI+0.60: No priced-in read yet
In context: The Phase 2 SUNRISE-PD trial demonstrated that 25% of patients saw meaningful improvement compared to 4% for placebo, with a specific benefit for patients with higher systemic inflammation.
Read from the article alone

BioVie reports positive Phase 2 Parkinson's data for bezisterim

BIVINew
biotech▲16%
IXI
clinical trials
drug development
inflammation
neurology
parkinsons

BioVie reports positive Phase 2 Parkinson's data for bezisterim

What matters in this story

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

BioVie reports positive Phase 2 Parkinson's data for bezisterim

What matters in this story

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

How each ticker is affected

Connected tickers

Track these names every morning.

Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

BioVie reports positive Phase 2 Parkinson's data for bezisterim

What matters in this story

Next reads from the same story arc

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

BioVie reports positive Phase 2 Parkinson's data for bezisterim

What matters in this story

Next reads from the same story arc

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

How each ticker is affected

Connected tickers

Track these names every morning.

Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer